Medical Care
Global Viral Vector and Plasmid DNA Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
- Jun 28, 25
- ID: 341387
- Pages: 164
- Figures: 167
- Views: 2
In 2024, the global market size of Viral Vector and Plasmid DNA was estimated to be worth US$ 948 million and is forecast to reach approximately US$ 3206 million by 2031 with a CAGR of 19.3% during the forecast period 2025-2031.
Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.
Global Viral Vector and Plasmid DNA key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Europe, and Asia-Pacific, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Viral Vector and Plasmid DNA, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector and Plasmid DNA.
The Viral Vector and Plasmid DNA market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Viral Vector and Plasmid DNA market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vector and Plasmid DNA companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Brammer Bio
Oxford BioMedica
Cobra Biologics
FinVector
Lonza
BioReliance
MolMed
FUJIFILM Diosynth Biotechnologies
UniQure
Aldevron
Richter-Helm
Eurogentec
OBiO Technology
Yposkesi
Cell and Gene Therapy Catapult
MassBiologics
Biovian
VGXI
Gene Synthesis
PlasmidFactory
Jikai Gene
Segment by Type
Plasmid DNA
Viral Vector
Segment by Application
Cancer
Virus Infection
Hereditary Disease
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Viral Vector and Plasmid DNA in global and regional level.
Chapter 3: Detailed analysis of Viral Vector and Plasmid DNA company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Vector and Plasmid DNA revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.
Global Viral Vector and Plasmid DNA key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Europe, and Asia-Pacific, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Viral Vector and Plasmid DNA, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector and Plasmid DNA.
The Viral Vector and Plasmid DNA market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Viral Vector and Plasmid DNA market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vector and Plasmid DNA companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Brammer Bio
Oxford BioMedica
Cobra Biologics
FinVector
Lonza
BioReliance
MolMed
FUJIFILM Diosynth Biotechnologies
UniQure
Aldevron
Richter-Helm
Eurogentec
OBiO Technology
Yposkesi
Cell and Gene Therapy Catapult
MassBiologics
Biovian
VGXI
Gene Synthesis
PlasmidFactory
Jikai Gene
Segment by Type
Plasmid DNA
Viral Vector
Segment by Application
Cancer
Virus Infection
Hereditary Disease
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Viral Vector and Plasmid DNA in global and regional level.
Chapter 3: Detailed analysis of Viral Vector and Plasmid DNA company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Vector and Plasmid DNA revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
1 Study Coverage
1.1 Viral Vector and Plasmid DNA Product Introduction
1.2 Market by Type
1.2.1 Global Viral Vector and Plasmid DNA Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Plasmid DNA
1.2.3 Viral Vector
1.3 Market by Application
1.3.1 Global Viral Vector and Plasmid DNA Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Cancer
1.3.3 Virus Infection
1.3.4 Hereditary Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Viral Vector and Plasmid DNA Market Size Estimates and Forecasts
2.2 Viral Vector and Plasmid DNA Market Size by Region: 2024 Versus 2031
2.2.1 Global Viral Vector and Plasmid DNA Revenue by Region: 2020-2025
2.2.2 Global Viral Vector and Plasmid DNA Revenue Forecast by Region (2026-2031)
2.2.3 Global Viral Vector and Plasmid DNA Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Viral Vector and Plasmid DNA Revenue by Type (2020-2031)
3.1.2 Global Viral Vector and Plasmid DNA Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Viral Vector and Plasmid DNA Revenue by Application (2020-2031)
3.2.2 Global Viral Vector and Plasmid DNA Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Plasmid DNA of Viral Vector and Plasmid DNA Revenue Market Share by Application
3.3.2 Viral Vector of Viral Vector and Plasmid DNA Revenue Market Share by Application
4 Global Viral Vector and Plasmid DNA by Company
4.1 Global Viral Vector and Plasmid DNA Revenue by Company (2020-2025)
4.2 Global Viral Vector and Plasmid DNA Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Viral Vector and Plasmid DNA Companies around the World: Ranking by Revenue
4.3.2 Global Viral Vector and Plasmid DNA Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Viral Vector and Plasmid DNA Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Viral Vector and Plasmid DNA Companies Headquarters & Product Type
4.4.1 Global Viral Vector and Plasmid DNA Companies Headquarters
4.4.2 Date of International Companies Enter into Viral Vector and Plasmid DNA Market
4.4.3 Global Viral Vector and Plasmid DNA Companies Product & Service
4.4.4 Plasmid DNA Revenue Market Share of Viral Vector and Plasmid DNA by Company
4.4.5 Viral Vector Revenue Market Share of Viral Vector and Plasmid DNA by Company
4.5 Global Viral Vector and Plasmid DNA Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Brammer Bio
5.1.1 Brammer Bio Corporation Information
5.1.2 Brammer Bio Description, Business Overview
5.1.3 Brammer Bio Viral Vector and Plasmid DNA Products Offered
5.1.4 Brammer Bio Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.1.5 Brammer Bio Viral Vector and Plasmid DNA Revenue by Product in 2024
5.1.6 Brammer Bio Viral Vector and Plasmid DNA Revenue by Application in 2024
5.1.7 Brammer Bio Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.1.8 Brammer Bio Recent Developments
5.2 Oxford BioMedica
5.2.1 Oxford BioMedica Corporation Information
5.2.2 Oxford BioMedica Description, Business Overview
5.2.3 Oxford BioMedica Viral Vector and Plasmid DNA Products Offered
5.2.4 Oxford BioMedica Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.2.5 Oxford BioMedica Viral Vector and Plasmid DNA Revenue by Product in 2024
5.2.6 Oxford BioMedica Viral Vector and Plasmid DNA Revenue by Application in 2024
5.2.7 Oxford BioMedica Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.2.8 Oxford BioMedica Recent Developments
5.3 Cobra Biologics
5.3.1 Cobra Biologics Corporation Information
5.3.2 Cobra Biologics Description, Business Overview
5.3.3 Cobra Biologics Viral Vector and Plasmid DNA Products Offered
5.3.4 Cobra Biologics Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.3.5 Cobra Biologics Viral Vector and Plasmid DNA Revenue by Product in 2024
5.3.6 Cobra Biologics Viral Vector and Plasmid DNA Revenue by Application in 2024
5.3.7 Cobra Biologics Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.3.8 Cobra Biologics Recent Developments
5.4 FinVector
5.4.1 FinVector Corporation Information
5.4.2 FinVector Description, Business Overview
5.4.3 FinVector Viral Vector and Plasmid DNA Products Offered
5.4.4 FinVector Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.4.5 FinVector Viral Vector and Plasmid DNA Revenue by Product in 2024
5.4.6 FinVector Viral Vector and Plasmid DNA Revenue by Application in 2024
5.4.7 FinVector Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.4.8 FinVector Recent Developments
5.5 Lonza
5.5.1 Lonza Corporation Information
5.5.2 Lonza Description, Business Overview
5.5.3 Lonza Viral Vector and Plasmid DNA Products Offered
5.5.4 Lonza Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.5.5 Lonza Viral Vector and Plasmid DNA Revenue by Product in 2024
5.5.6 Lonza Viral Vector and Plasmid DNA Revenue by Application in 2024
5.5.7 Lonza Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.5.8 Lonza Recent Developments
5.6 BioReliance
5.6.1 BioReliance Corporation Information
5.6.2 BioReliance Description, Business Overview
5.6.3 BioReliance Viral Vector and Plasmid DNA Products Offered
5.6.4 BioReliance Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.6.5 BioReliance Viral Vector and Plasmid DNA Revenue by Product in 2024
5.6.6 BioReliance Viral Vector and Plasmid DNA Revenue by Application in 2024
5.6.7 BioReliance Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.6.8 BioReliance Recent Developments
5.7 MolMed
5.7.1 MolMed Corporation Information
5.7.2 MolMed Description, Business Overview
5.7.3 MolMed Viral Vector and Plasmid DNA Products Offered
5.7.4 MolMed Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.7.5 MolMed Viral Vector and Plasmid DNA Revenue by Product in 2024
5.7.6 MolMed Viral Vector and Plasmid DNA Revenue by Application in 2024
5.7.7 MolMed Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.7.8 MolMed Recent Developments
5.8 FUJIFILM Diosynth Biotechnologies
5.8.1 FUJIFILM Diosynth Biotechnologies Corporation Information
5.8.2 FUJIFILM Diosynth Biotechnologies Description, Business Overview
5.8.3 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Products Offered
5.8.4 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.8.5 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue by Product in 2024
5.8.6 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue by Application in 2024
5.8.7 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.8.8 FUJIFILM Diosynth Biotechnologies Recent Developments
5.9 UniQure
5.9.1 UniQure Corporation Information
5.9.2 UniQure Description, Business Overview
5.9.3 UniQure Viral Vector and Plasmid DNA Products Offered
5.9.4 UniQure Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.9.5 UniQure Viral Vector and Plasmid DNA Revenue by Product in 2024
5.9.6 UniQure Viral Vector and Plasmid DNA Revenue by Application in 2024
5.9.7 UniQure Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.9.8 UniQure Recent Developments
5.10 Aldevron
5.10.1 Aldevron Corporation Information
5.10.2 Aldevron Description, Business Overview
5.10.3 Aldevron Viral Vector and Plasmid DNA Products Offered
5.10.4 Aldevron Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.10.5 Aldevron Viral Vector and Plasmid DNA Revenue by Product in 2024
5.10.6 Aldevron Viral Vector and Plasmid DNA Revenue by Application in 2024
5.10.7 Aldevron Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.10.8 Aldevron Recent Developments
5.11 Richter-Helm
5.11.1 Richter-Helm Corporation Information
5.11.2 Richter-Helm Description, Business Overview
5.11.3 Richter-Helm Viral Vector and Plasmid DNA Products Offered
5.11.4 Richter-Helm Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.11.5 Richter-Helm Viral Vector and Plasmid DNA Revenue by Product in 2024
5.11.6 Richter-Helm Viral Vector and Plasmid DNA Revenue by Application in 2024
5.11.7 Richter-Helm Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.11.8 Richter-Helm Recent Developments
5.12 Eurogentec
5.12.1 Eurogentec Corporation Information
5.12.2 Eurogentec Description, Business Overview
5.12.3 Eurogentec Viral Vector and Plasmid DNA Products Offered
5.12.4 Eurogentec Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.12.5 Eurogentec Viral Vector and Plasmid DNA Revenue by Product in 2024
5.12.6 Eurogentec Viral Vector and Plasmid DNA Revenue by Application in 2024
5.12.7 Eurogentec Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.12.8 Eurogentec Recent Developments
5.13 OBiO Technology
5.13.1 OBiO Technology Corporation Information
5.13.2 OBiO Technology Description, Business Overview
5.13.3 OBiO Technology Viral Vector and Plasmid DNA Products Offered
5.13.4 OBiO Technology Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.13.5 OBiO Technology Viral Vector and Plasmid DNA Revenue by Product in 2024
5.13.6 OBiO Technology Viral Vector and Plasmid DNA Revenue by Application in 2024
5.13.7 OBiO Technology Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.13.8 OBiO Technology Recent Developments
5.14 Yposkesi
5.14.1 Yposkesi Corporation Information
5.14.2 Yposkesi Description, Business Overview
5.14.3 Yposkesi Viral Vector and Plasmid DNA Products Offered
5.14.4 Yposkesi Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.14.5 Yposkesi Viral Vector and Plasmid DNA Revenue by Product in 2024
5.14.6 Yposkesi Viral Vector and Plasmid DNA Revenue by Application in 2024
5.14.7 Yposkesi Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.14.8 Yposkesi Recent Developments
5.15 Cell and Gene Therapy Catapult
5.15.1 Cell and Gene Therapy Catapult Corporation Information
5.15.2 Cell and Gene Therapy Catapult Description, Business Overview
5.15.3 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Products Offered
5.15.4 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.15.5 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue by Product in 2024
5.15.6 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue by Application in 2024
5.15.7 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.15.8 Cell and Gene Therapy Catapult Recent Developments
5.16 MassBiologics
5.16.1 MassBiologics Corporation Information
5.16.2 MassBiologics Description, Business Overview
5.16.3 MassBiologics Viral Vector and Plasmid DNA Products Offered
5.16.4 MassBiologics Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.16.5 MassBiologics Viral Vector and Plasmid DNA Revenue by Product in 2024
5.16.6 MassBiologics Viral Vector and Plasmid DNA Revenue by Application in 2024
5.16.7 MassBiologics Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.16.8 MassBiologics Recent Developments
5.17 Biovian
5.17.1 Biovian Corporation Information
5.17.2 Biovian Description, Business Overview
5.17.3 Biovian Viral Vector and Plasmid DNA Products Offered
5.17.4 Biovian Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.17.5 Biovian Viral Vector and Plasmid DNA Revenue by Product in 2024
5.17.6 Biovian Viral Vector and Plasmid DNA Revenue by Application in 2024
5.17.7 Biovian Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.17.8 Biovian Recent Developments
5.18 VGXI
5.18.1 VGXI Corporation Information
5.18.2 VGXI Description, Business Overview
5.18.3 VGXI Viral Vector and Plasmid DNA Products Offered
5.18.4 VGXI Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.18.5 VGXI Viral Vector and Plasmid DNA Revenue by Product in 2024
5.18.6 VGXI Viral Vector and Plasmid DNA Revenue by Application in 2024
5.18.7 VGXI Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.18.8 VGXI Recent Developments
5.19 Gene Synthesis
5.19.1 Gene Synthesis Corporation Information
5.19.2 Gene Synthesis Description, Business Overview
5.19.3 Gene Synthesis Viral Vector and Plasmid DNA Products Offered
5.19.4 Gene Synthesis Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.19.5 Gene Synthesis Viral Vector and Plasmid DNA Revenue by Product in 2024
5.19.6 Gene Synthesis Viral Vector and Plasmid DNA Revenue by Application in 2024
5.19.7 Gene Synthesis Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.19.8 Gene Synthesis Recent Developments
5.20 PlasmidFactory
5.20.1 PlasmidFactory Corporation Information
5.20.2 PlasmidFactory Description, Business Overview
5.20.3 PlasmidFactory Viral Vector and Plasmid DNA Products Offered
5.20.4 PlasmidFactory Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.20.5 PlasmidFactory Viral Vector and Plasmid DNA Revenue by Product in 2024
5.20.6 PlasmidFactory Viral Vector and Plasmid DNA Revenue by Application in 2024
5.20.7 PlasmidFactory Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.20.8 PlasmidFactory Recent Developments
5.21 Jikai Gene
5.21.1 Jikai Gene Corporation Information
5.21.2 Jikai Gene Description, Business Overview
5.21.3 Jikai Gene Viral Vector and Plasmid DNA Products Offered
5.21.4 Jikai Gene Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.21.5 Jikai Gene Viral Vector and Plasmid DNA Revenue by Product in 2024
5.21.6 Jikai Gene Viral Vector and Plasmid DNA Revenue by Application in 2024
5.21.7 Jikai Gene Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.21.8 Jikai Gene Recent Developments
6 North America
6.1 North America Viral Vector and Plasmid DNA Market Size YoY Growth 2020-2031
6.2 North America Viral Vector and Plasmid DNA Market Facts & Figures by Country (2020-2031)
6.3 North America Viral Vector and Plasmid DNA Revenue by Type (2020-2025)
6.4 North America Viral Vector and Plasmid DNA Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Viral Vector and Plasmid DNA Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Viral Vector and Plasmid DNA Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Viral Vector and Plasmid DNA Revenue by Type (2020-2025)
7.4 Asia-Pacific Viral Vector and Plasmid DNA Revenue by Application (2020-2025)
8 Europe
8.1 Europe Viral Vector and Plasmid DNA Market Size YoY Growth 2020-2031
8.2 Europe Viral Vector and Plasmid DNA Market Facts & Figures by Country (2020-2031)
8.3 Europe Viral Vector and Plasmid DNA Revenue by Type (2020-2025)
8.4 Europe Viral Vector and Plasmid DNA Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Viral Vector and Plasmid DNA Market Size YoY Growth 2020-2031
9.2 Latin America Viral Vector and Plasmid DNA Market Facts & Figures by Country (2020-2031)
9.3 Latin America Viral Vector and Plasmid DNA Revenue by Type (2020-2025)
9.4 Latin America Viral Vector and Plasmid DNA Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Viral Vector and Plasmid DNA Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Viral Vector and Plasmid DNA Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Viral Vector and Plasmid DNA Revenue by Type (2020-2025)
10.4 Middle East and Africa Viral Vector and Plasmid DNA Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Viral Vector and Plasmid DNA Supply Chain Analysis
11.2 Viral Vector and Plasmid DNA Key Raw Materials and Upstream Suppliers
11.3 Viral Vector and Plasmid DNA Clients Analysis
11.4 Viral Vector and Plasmid DNA Sales Channel and Sales Model Analysis
11.4.1 Viral Vector and Plasmid DNA Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Viral Vector and Plasmid DNA Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Viral Vector and Plasmid DNA Distributors
12 Viral Vector and Plasmid DNA Market Dynamics
12.1 Viral Vector and Plasmid DNA Industry Trends
12.2 Viral Vector and Plasmid DNA Market Drivers
12.3 Viral Vector and Plasmid DNA Market Challenges
12.4 Viral Vector and Plasmid DNA Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1.1 Viral Vector and Plasmid DNA Product Introduction
1.2 Market by Type
1.2.1 Global Viral Vector and Plasmid DNA Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Plasmid DNA
1.2.3 Viral Vector
1.3 Market by Application
1.3.1 Global Viral Vector and Plasmid DNA Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Cancer
1.3.3 Virus Infection
1.3.4 Hereditary Disease
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Viral Vector and Plasmid DNA Market Size Estimates and Forecasts
2.2 Viral Vector and Plasmid DNA Market Size by Region: 2024 Versus 2031
2.2.1 Global Viral Vector and Plasmid DNA Revenue by Region: 2020-2025
2.2.2 Global Viral Vector and Plasmid DNA Revenue Forecast by Region (2026-2031)
2.2.3 Global Viral Vector and Plasmid DNA Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Viral Vector and Plasmid DNA Revenue by Type (2020-2031)
3.1.2 Global Viral Vector and Plasmid DNA Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Viral Vector and Plasmid DNA Revenue by Application (2020-2031)
3.2.2 Global Viral Vector and Plasmid DNA Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Plasmid DNA of Viral Vector and Plasmid DNA Revenue Market Share by Application
3.3.2 Viral Vector of Viral Vector and Plasmid DNA Revenue Market Share by Application
4 Global Viral Vector and Plasmid DNA by Company
4.1 Global Viral Vector and Plasmid DNA Revenue by Company (2020-2025)
4.2 Global Viral Vector and Plasmid DNA Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Viral Vector and Plasmid DNA Companies around the World: Ranking by Revenue
4.3.2 Global Viral Vector and Plasmid DNA Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Viral Vector and Plasmid DNA Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Viral Vector and Plasmid DNA Companies Headquarters & Product Type
4.4.1 Global Viral Vector and Plasmid DNA Companies Headquarters
4.4.2 Date of International Companies Enter into Viral Vector and Plasmid DNA Market
4.4.3 Global Viral Vector and Plasmid DNA Companies Product & Service
4.4.4 Plasmid DNA Revenue Market Share of Viral Vector and Plasmid DNA by Company
4.4.5 Viral Vector Revenue Market Share of Viral Vector and Plasmid DNA by Company
4.5 Global Viral Vector and Plasmid DNA Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Brammer Bio
5.1.1 Brammer Bio Corporation Information
5.1.2 Brammer Bio Description, Business Overview
5.1.3 Brammer Bio Viral Vector and Plasmid DNA Products Offered
5.1.4 Brammer Bio Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.1.5 Brammer Bio Viral Vector and Plasmid DNA Revenue by Product in 2024
5.1.6 Brammer Bio Viral Vector and Plasmid DNA Revenue by Application in 2024
5.1.7 Brammer Bio Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.1.8 Brammer Bio Recent Developments
5.2 Oxford BioMedica
5.2.1 Oxford BioMedica Corporation Information
5.2.2 Oxford BioMedica Description, Business Overview
5.2.3 Oxford BioMedica Viral Vector and Plasmid DNA Products Offered
5.2.4 Oxford BioMedica Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.2.5 Oxford BioMedica Viral Vector and Plasmid DNA Revenue by Product in 2024
5.2.6 Oxford BioMedica Viral Vector and Plasmid DNA Revenue by Application in 2024
5.2.7 Oxford BioMedica Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.2.8 Oxford BioMedica Recent Developments
5.3 Cobra Biologics
5.3.1 Cobra Biologics Corporation Information
5.3.2 Cobra Biologics Description, Business Overview
5.3.3 Cobra Biologics Viral Vector and Plasmid DNA Products Offered
5.3.4 Cobra Biologics Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.3.5 Cobra Biologics Viral Vector and Plasmid DNA Revenue by Product in 2024
5.3.6 Cobra Biologics Viral Vector and Plasmid DNA Revenue by Application in 2024
5.3.7 Cobra Biologics Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.3.8 Cobra Biologics Recent Developments
5.4 FinVector
5.4.1 FinVector Corporation Information
5.4.2 FinVector Description, Business Overview
5.4.3 FinVector Viral Vector and Plasmid DNA Products Offered
5.4.4 FinVector Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.4.5 FinVector Viral Vector and Plasmid DNA Revenue by Product in 2024
5.4.6 FinVector Viral Vector and Plasmid DNA Revenue by Application in 2024
5.4.7 FinVector Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.4.8 FinVector Recent Developments
5.5 Lonza
5.5.1 Lonza Corporation Information
5.5.2 Lonza Description, Business Overview
5.5.3 Lonza Viral Vector and Plasmid DNA Products Offered
5.5.4 Lonza Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.5.5 Lonza Viral Vector and Plasmid DNA Revenue by Product in 2024
5.5.6 Lonza Viral Vector and Plasmid DNA Revenue by Application in 2024
5.5.7 Lonza Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.5.8 Lonza Recent Developments
5.6 BioReliance
5.6.1 BioReliance Corporation Information
5.6.2 BioReliance Description, Business Overview
5.6.3 BioReliance Viral Vector and Plasmid DNA Products Offered
5.6.4 BioReliance Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.6.5 BioReliance Viral Vector and Plasmid DNA Revenue by Product in 2024
5.6.6 BioReliance Viral Vector and Plasmid DNA Revenue by Application in 2024
5.6.7 BioReliance Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.6.8 BioReliance Recent Developments
5.7 MolMed
5.7.1 MolMed Corporation Information
5.7.2 MolMed Description, Business Overview
5.7.3 MolMed Viral Vector and Plasmid DNA Products Offered
5.7.4 MolMed Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.7.5 MolMed Viral Vector and Plasmid DNA Revenue by Product in 2024
5.7.6 MolMed Viral Vector and Plasmid DNA Revenue by Application in 2024
5.7.7 MolMed Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.7.8 MolMed Recent Developments
5.8 FUJIFILM Diosynth Biotechnologies
5.8.1 FUJIFILM Diosynth Biotechnologies Corporation Information
5.8.2 FUJIFILM Diosynth Biotechnologies Description, Business Overview
5.8.3 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Products Offered
5.8.4 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.8.5 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue by Product in 2024
5.8.6 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue by Application in 2024
5.8.7 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.8.8 FUJIFILM Diosynth Biotechnologies Recent Developments
5.9 UniQure
5.9.1 UniQure Corporation Information
5.9.2 UniQure Description, Business Overview
5.9.3 UniQure Viral Vector and Plasmid DNA Products Offered
5.9.4 UniQure Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.9.5 UniQure Viral Vector and Plasmid DNA Revenue by Product in 2024
5.9.6 UniQure Viral Vector and Plasmid DNA Revenue by Application in 2024
5.9.7 UniQure Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.9.8 UniQure Recent Developments
5.10 Aldevron
5.10.1 Aldevron Corporation Information
5.10.2 Aldevron Description, Business Overview
5.10.3 Aldevron Viral Vector and Plasmid DNA Products Offered
5.10.4 Aldevron Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.10.5 Aldevron Viral Vector and Plasmid DNA Revenue by Product in 2024
5.10.6 Aldevron Viral Vector and Plasmid DNA Revenue by Application in 2024
5.10.7 Aldevron Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.10.8 Aldevron Recent Developments
5.11 Richter-Helm
5.11.1 Richter-Helm Corporation Information
5.11.2 Richter-Helm Description, Business Overview
5.11.3 Richter-Helm Viral Vector and Plasmid DNA Products Offered
5.11.4 Richter-Helm Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.11.5 Richter-Helm Viral Vector and Plasmid DNA Revenue by Product in 2024
5.11.6 Richter-Helm Viral Vector and Plasmid DNA Revenue by Application in 2024
5.11.7 Richter-Helm Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.11.8 Richter-Helm Recent Developments
5.12 Eurogentec
5.12.1 Eurogentec Corporation Information
5.12.2 Eurogentec Description, Business Overview
5.12.3 Eurogentec Viral Vector and Plasmid DNA Products Offered
5.12.4 Eurogentec Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.12.5 Eurogentec Viral Vector and Plasmid DNA Revenue by Product in 2024
5.12.6 Eurogentec Viral Vector and Plasmid DNA Revenue by Application in 2024
5.12.7 Eurogentec Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.12.8 Eurogentec Recent Developments
5.13 OBiO Technology
5.13.1 OBiO Technology Corporation Information
5.13.2 OBiO Technology Description, Business Overview
5.13.3 OBiO Technology Viral Vector and Plasmid DNA Products Offered
5.13.4 OBiO Technology Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.13.5 OBiO Technology Viral Vector and Plasmid DNA Revenue by Product in 2024
5.13.6 OBiO Technology Viral Vector and Plasmid DNA Revenue by Application in 2024
5.13.7 OBiO Technology Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.13.8 OBiO Technology Recent Developments
5.14 Yposkesi
5.14.1 Yposkesi Corporation Information
5.14.2 Yposkesi Description, Business Overview
5.14.3 Yposkesi Viral Vector and Plasmid DNA Products Offered
5.14.4 Yposkesi Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.14.5 Yposkesi Viral Vector and Plasmid DNA Revenue by Product in 2024
5.14.6 Yposkesi Viral Vector and Plasmid DNA Revenue by Application in 2024
5.14.7 Yposkesi Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.14.8 Yposkesi Recent Developments
5.15 Cell and Gene Therapy Catapult
5.15.1 Cell and Gene Therapy Catapult Corporation Information
5.15.2 Cell and Gene Therapy Catapult Description, Business Overview
5.15.3 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Products Offered
5.15.4 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.15.5 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue by Product in 2024
5.15.6 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue by Application in 2024
5.15.7 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.15.8 Cell and Gene Therapy Catapult Recent Developments
5.16 MassBiologics
5.16.1 MassBiologics Corporation Information
5.16.2 MassBiologics Description, Business Overview
5.16.3 MassBiologics Viral Vector and Plasmid DNA Products Offered
5.16.4 MassBiologics Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.16.5 MassBiologics Viral Vector and Plasmid DNA Revenue by Product in 2024
5.16.6 MassBiologics Viral Vector and Plasmid DNA Revenue by Application in 2024
5.16.7 MassBiologics Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.16.8 MassBiologics Recent Developments
5.17 Biovian
5.17.1 Biovian Corporation Information
5.17.2 Biovian Description, Business Overview
5.17.3 Biovian Viral Vector and Plasmid DNA Products Offered
5.17.4 Biovian Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.17.5 Biovian Viral Vector and Plasmid DNA Revenue by Product in 2024
5.17.6 Biovian Viral Vector and Plasmid DNA Revenue by Application in 2024
5.17.7 Biovian Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.17.8 Biovian Recent Developments
5.18 VGXI
5.18.1 VGXI Corporation Information
5.18.2 VGXI Description, Business Overview
5.18.3 VGXI Viral Vector and Plasmid DNA Products Offered
5.18.4 VGXI Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.18.5 VGXI Viral Vector and Plasmid DNA Revenue by Product in 2024
5.18.6 VGXI Viral Vector and Plasmid DNA Revenue by Application in 2024
5.18.7 VGXI Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.18.8 VGXI Recent Developments
5.19 Gene Synthesis
5.19.1 Gene Synthesis Corporation Information
5.19.2 Gene Synthesis Description, Business Overview
5.19.3 Gene Synthesis Viral Vector and Plasmid DNA Products Offered
5.19.4 Gene Synthesis Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.19.5 Gene Synthesis Viral Vector and Plasmid DNA Revenue by Product in 2024
5.19.6 Gene Synthesis Viral Vector and Plasmid DNA Revenue by Application in 2024
5.19.7 Gene Synthesis Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.19.8 Gene Synthesis Recent Developments
5.20 PlasmidFactory
5.20.1 PlasmidFactory Corporation Information
5.20.2 PlasmidFactory Description, Business Overview
5.20.3 PlasmidFactory Viral Vector and Plasmid DNA Products Offered
5.20.4 PlasmidFactory Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.20.5 PlasmidFactory Viral Vector and Plasmid DNA Revenue by Product in 2024
5.20.6 PlasmidFactory Viral Vector and Plasmid DNA Revenue by Application in 2024
5.20.7 PlasmidFactory Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.20.8 PlasmidFactory Recent Developments
5.21 Jikai Gene
5.21.1 Jikai Gene Corporation Information
5.21.2 Jikai Gene Description, Business Overview
5.21.3 Jikai Gene Viral Vector and Plasmid DNA Products Offered
5.21.4 Jikai Gene Viral Vector and Plasmid DNA Revenue and Gross Margin (2020-2025)
5.21.5 Jikai Gene Viral Vector and Plasmid DNA Revenue by Product in 2024
5.21.6 Jikai Gene Viral Vector and Plasmid DNA Revenue by Application in 2024
5.21.7 Jikai Gene Viral Vector and Plasmid DNA Revenue by Geographic Area in 2024
5.21.8 Jikai Gene Recent Developments
6 North America
6.1 North America Viral Vector and Plasmid DNA Market Size YoY Growth 2020-2031
6.2 North America Viral Vector and Plasmid DNA Market Facts & Figures by Country (2020-2031)
6.3 North America Viral Vector and Plasmid DNA Revenue by Type (2020-2025)
6.4 North America Viral Vector and Plasmid DNA Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Viral Vector and Plasmid DNA Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Viral Vector and Plasmid DNA Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Viral Vector and Plasmid DNA Revenue by Type (2020-2025)
7.4 Asia-Pacific Viral Vector and Plasmid DNA Revenue by Application (2020-2025)
8 Europe
8.1 Europe Viral Vector and Plasmid DNA Market Size YoY Growth 2020-2031
8.2 Europe Viral Vector and Plasmid DNA Market Facts & Figures by Country (2020-2031)
8.3 Europe Viral Vector and Plasmid DNA Revenue by Type (2020-2025)
8.4 Europe Viral Vector and Plasmid DNA Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Viral Vector and Plasmid DNA Market Size YoY Growth 2020-2031
9.2 Latin America Viral Vector and Plasmid DNA Market Facts & Figures by Country (2020-2031)
9.3 Latin America Viral Vector and Plasmid DNA Revenue by Type (2020-2025)
9.4 Latin America Viral Vector and Plasmid DNA Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Viral Vector and Plasmid DNA Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Viral Vector and Plasmid DNA Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Viral Vector and Plasmid DNA Revenue by Type (2020-2025)
10.4 Middle East and Africa Viral Vector and Plasmid DNA Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Viral Vector and Plasmid DNA Supply Chain Analysis
11.2 Viral Vector and Plasmid DNA Key Raw Materials and Upstream Suppliers
11.3 Viral Vector and Plasmid DNA Clients Analysis
11.4 Viral Vector and Plasmid DNA Sales Channel and Sales Model Analysis
11.4.1 Viral Vector and Plasmid DNA Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Viral Vector and Plasmid DNA Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Viral Vector and Plasmid DNA Distributors
12 Viral Vector and Plasmid DNA Market Dynamics
12.1 Viral Vector and Plasmid DNA Industry Trends
12.2 Viral Vector and Plasmid DNA Market Drivers
12.3 Viral Vector and Plasmid DNA Market Challenges
12.4 Viral Vector and Plasmid DNA Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Viral Vector and Plasmid DNA Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Viral Vector and Plasmid DNA Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Viral Vector and Plasmid DNA Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Viral Vector and Plasmid DNA Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Viral Vector and Plasmid DNA Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Viral Vector and Plasmid DNA Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Viral Vector and Plasmid DNA Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Viral Vector and Plasmid DNA Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Viral Vector and Plasmid DNA Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Viral Vector and Plasmid DNA Revenue by Company (2020-2025) & (US$ Million)
Table 11. Viral Vector and Plasmid DNA Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Viral Vector and Plasmid DNA Players by Revenue (US$ Million) in 2024
Table 13. Global Viral Vector and Plasmid DNA Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Viral Vector and Plasmid DNA by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector and Plasmid DNA as of 2024)
Table 15. Global Viral Vector and Plasmid DNA Companies Headquarters
Table 16. Date of International Companies Enter into Viral Vector and Plasmid DNA Market
Table 17. Global Viral Vector and Plasmid DNA Companies Product & Service
Table 18. Global Viral Vector and Plasmid DNA Mergers & Acquisitions, Expansion Plans
Table 19. Brammer Bio Corporation Information
Table 20. Brammer Bio Description and Business Overview
Table 21. Brammer Bio Viral Vector and Plasmid DNA Product
Table 22. Brammer Bio Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Brammer Bio Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 24. Brammer Bio Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 25. Brammer Bio Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 26. Brammer Bio Recent Developments
Table 27. Oxford BioMedica Corporation Information
Table 28. Oxford BioMedica Description and Business Overview
Table 29. Oxford BioMedica Viral Vector and Plasmid DNA Product
Table 30. Oxford BioMedica Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Oxford BioMedica Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 32. Oxford BioMedica Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 33. Oxford BioMedica Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 34. Oxford BioMedica Recent Developments
Table 35. Cobra Biologics Corporation Information
Table 36. Cobra Biologics Description and Business Overview
Table 37. Cobra Biologics Viral Vector and Plasmid DNA Product
Table 38. Cobra Biologics Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Cobra Biologics Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 40. Cobra Biologics Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 41. Cobra Biologics Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 42. Cobra Biologics Recent Developments
Table 43. FinVector Corporation Information
Table 44. FinVector Description and Business Overview
Table 45. FinVector Viral Vector and Plasmid DNA Product
Table 46. FinVector Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. FinVector Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 48. FinVector Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 49. FinVector Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 50. FinVector Recent Developments
Table 51. Lonza Corporation Information
Table 52. Lonza Description and Business Overview
Table 53. Lonza Viral Vector and Plasmid DNA Product
Table 54. Lonza Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Lonza Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 56. Lonza Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 57. Lonza Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 58. Lonza Recent Developments
Table 59. BioReliance Corporation Information
Table 60. BioReliance Description and Business Overview
Table 61. BioReliance Viral Vector and Plasmid DNA Product
Table 62. BioReliance Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. BioReliance Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 64. BioReliance Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 65. BioReliance Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 66. BioReliance Recent Developments
Table 67. MolMed Corporation Information
Table 68. MolMed Description and Business Overview
Table 69. MolMed Viral Vector and Plasmid DNA Product
Table 70. MolMed Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. MolMed Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 72. MolMed Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 73. MolMed Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 74. MolMed Recent Developments
Table 75. FUJIFILM Diosynth Biotechnologies Corporation Information
Table 76. FUJIFILM Diosynth Biotechnologies Description and Business Overview
Table 77. FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Product
Table 78. FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. FUJIFILM Diosynth Biotechnologies Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 80. FUJIFILM Diosynth Biotechnologies Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 81. FUJIFILM Diosynth Biotechnologies Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 82. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 83. UniQure Corporation Information
Table 84. UniQure Description and Business Overview
Table 85. UniQure Viral Vector and Plasmid DNA Product
Table 86. UniQure Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. UniQure Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 88. UniQure Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 89. UniQure Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 90. UniQure Recent Developments
Table 91. Aldevron Corporation Information
Table 92. Aldevron Description and Business Overview
Table 93. Aldevron Viral Vector and Plasmid DNA Product
Table 94. Aldevron Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. Aldevron Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 96. Aldevron Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 97. Aldevron Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 98. Aldevron Recent Developments
Table 99. Richter-Helm Corporation Information
Table 100. Richter-Helm Description and Business Overview
Table 101. Richter-Helm Viral Vector and Plasmid DNA Product
Table 102. Richter-Helm Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Richter-Helm Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 104. Richter-Helm Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 105. Richter-Helm Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 106. Richter-Helm Recent Developments
Table 107. Eurogentec Corporation Information
Table 108. Eurogentec Description and Business Overview
Table 109. Eurogentec Viral Vector and Plasmid DNA Product
Table 110. Eurogentec Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 111. Eurogentec Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 112. Eurogentec Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 113. Eurogentec Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 114. Eurogentec Recent Developments
Table 115. OBiO Technology Corporation Information
Table 116. OBiO Technology Description and Business Overview
Table 117. OBiO Technology Viral Vector and Plasmid DNA Product
Table 118. OBiO Technology Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 119. OBiO Technology Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 120. OBiO Technology Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 121. OBiO Technology Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 122. OBiO Technology Recent Developments
Table 123. Yposkesi Corporation Information
Table 124. Yposkesi Description and Business Overview
Table 125. Yposkesi Viral Vector and Plasmid DNA Product
Table 126. Yposkesi Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 127. Yposkesi Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 128. Yposkesi Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 129. Yposkesi Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 130. Yposkesi Recent Developments
Table 131. Cell and Gene Therapy Catapult Corporation Information
Table 132. Cell and Gene Therapy Catapult Description and Business Overview
Table 133. Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Product
Table 134. Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 135. Cell and Gene Therapy Catapult Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 136. Cell and Gene Therapy Catapult Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 137. Cell and Gene Therapy Catapult Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 138. Cell and Gene Therapy Catapult Recent Developments
Table 139. MassBiologics Corporation Information
Table 140. MassBiologics Description and Business Overview
Table 141. MassBiologics Viral Vector and Plasmid DNA Product
Table 142. MassBiologics Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. MassBiologics Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 144. MassBiologics Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 145. MassBiologics Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 146. MassBiologics Recent Developments
Table 147. Biovian Corporation Information
Table 148. Biovian Description and Business Overview
Table 149. Biovian Viral Vector and Plasmid DNA Product
Table 150. Biovian Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 151. Biovian Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 152. Biovian Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 153. Biovian Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 154. Biovian Recent Developments
Table 155. VGXI Corporation Information
Table 156. VGXI Description and Business Overview
Table 157. VGXI Viral Vector and Plasmid DNA Product
Table 158. VGXI Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 159. VGXI Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 160. VGXI Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 161. VGXI Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 162. VGXI Recent Developments
Table 163. Gene Synthesis Corporation Information
Table 164. Gene Synthesis Description and Business Overview
Table 165. Gene Synthesis Viral Vector and Plasmid DNA Product
Table 166. Gene Synthesis Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 167. Gene Synthesis Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 168. Gene Synthesis Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 169. Gene Synthesis Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 170. Gene Synthesis Recent Developments
Table 171. PlasmidFactory Corporation Information
Table 172. PlasmidFactory Description and Business Overview
Table 173. PlasmidFactory Viral Vector and Plasmid DNA Product
Table 174. PlasmidFactory Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 175. PlasmidFactory Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 176. PlasmidFactory Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 177. PlasmidFactory Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 178. PlasmidFactory Recent Developments
Table 179. Jikai Gene Corporation Information
Table 180. Jikai Gene Description and Business Overview
Table 181. Jikai Gene Viral Vector and Plasmid DNA Product
Table 182. Jikai Gene Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 183. Jikai Gene Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 184. Jikai Gene Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 185. Jikai Gene Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 186. Jikai Gene Recent Developments
Table 187. North America Viral Vector and Plasmid DNA Revenue by Country (2020-2025) & (US$ Million)
Table 188. North America Viral Vector and Plasmid DNA Revenue by Country (2026-2031) & (US$ Million)
Table 189. North America Viral Vector and Plasmid DNA Revenue by Type (2020-2025) & (US$ Million)
Table 190. North America Viral Vector and Plasmid DNA Revenue by Application (2020-2025) & (US$ Million)
Table 191. Asia-Pacific Viral Vector and Plasmid DNA Revenue by Region (2020-2025) & (US$ Million)
Table 192. Asia-Pacific Viral Vector and Plasmid DNA Revenue by Region (2026-2031) & (US$ Million)
Table 193. Asia-Pacific Viral Vector and Plasmid DNA Revenue by Type (2020-2025) & (US$ Million)
Table 194. Asia-Pacific Viral Vector and Plasmid DNA Revenue by Application (2020-2025) & (US$ Million)
Table 195. Europe Viral Vector and Plasmid DNA Revenue by Country (2020-2025) & (US$ Million)
Table 196. Europe Viral Vector and Plasmid DNA Revenue by Country (2026-2031) & (US$ Million)
Table 197. Europe Viral Vector and Plasmid DNA Revenue by Type (2020-2025) & (US$ Million)
Table 198. Europe Viral Vector and Plasmid DNA Revenue by Application (2020-2025) & (US$ Million)
Table 199. Latin America Viral Vector and Plasmid DNA Revenue by Country (2020-2025) & (US$ Million)
Table 200. Latin America Viral Vector and Plasmid DNA Revenue by Country (2026-2031) & (US$ Million)
Table 201. Latin America Viral Vector and Plasmid DNA Revenue by Type (2020-2025) & (US$ Million)
Table 202. Latin America Viral Vector and Plasmid DNA Revenue by Application (2020-2025) & (US$ Million)
Table 203. Middle East and Africa Viral Vector and Plasmid DNA Revenue by Country (2020-2025) & (US$ Million)
Table 204. Middle East and Africa Viral Vector and Plasmid DNA Revenue by Country (2026-2031) & (US$ Million)
Table 205. Middle East and Africa Viral Vector and Plasmid DNA Revenue by Type (2020-2025) & (US$ Million)
Table 206. Middle East and Africa Viral Vector and Plasmid DNA Revenue by Application (2020-2025) & (US$ Million)
Table 207. Viral Vector and Plasmid DNA Key Raw Materials, Industry Status and Trend
Table 208. Viral Vector and Plasmid DNA Key Raw Materials and Upstream Suppliers
Table 209. Viral Vector and Plasmid DNA Clients Status and Trend
Table 210. Viral Vector and Plasmid DNA Typical Clients
Table 211. Viral Vector and Plasmid DNA Distributors
Table 212. Viral Vector and Plasmid DNA Market Trends
Table 213. Viral Vector and Plasmid DNA Market Drivers
Table 214. Viral Vector and Plasmid DNA Market Challenges
Table 215. Viral Vector and Plasmid DNA Market Restraints
Table 216. Research Programs/Design for This Report
Table 217. Key Data Information from Secondary Sources
Table 218. Key Data Information from Primary Sources
List of Figures
Figure 1. Viral Vector and Plasmid DNA Product Picture
Figure 2. Global Viral Vector and Plasmid DNA Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Viral Vector and Plasmid DNA Revenue Market Share by Type in 2024 & 2031
Figure 4. Plasmid DNA Product Picture
Figure 5. Viral Vector Product Picture
Figure 6. Global Viral Vector and Plasmid DNA Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 7. Global Viral Vector and Plasmid DNA Revenue Market Share by Application in 2024 & 2031
Figure 8. Cancer
Figure 9. Virus Infection
Figure 10. Hereditary Disease
Figure 11. Viral Vector and Plasmid DNA Report Years Considered
Figure 12. Global Viral Vector and Plasmid DNA Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Viral Vector and Plasmid DNA Market Size (2020-2031) & (US$ Million)
Figure 14. Global Viral Vector and Plasmid DNA Market Size Market Share by Region: 2024 Versus 2031
Figure 15. Global Viral Vector and Plasmid DNA Revenue Market Share by Region (2020-2031)
Figure 16. Global Viral Vector and Plasmid DNA Revenue Market Share Forecast by Type (2020-2031)
Figure 17. Global Viral Vector and Plasmid DNA Revenue Market Share Forecast by Application (2020-2031)
Figure 18. Plasmid DNA of Viral Vector and Plasmid DNA Revenue Market Share by Application, 2024 VS 2031
Figure 19. Viral Vector of Viral Vector and Plasmid DNA Revenue Market Share by Application, 2024 VS 2031
Figure 20. Viral Vector and Plasmid DNA Revenue Share by Company (2024)
Figure 21. Viral Vector and Plasmid DNA Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Plasmid DNA Revenue Proportion by Company in 2024
Figure 23. Viral Vector Revenue Proportion by Company in 2024
Figure 24. North America Viral Vector and Plasmid DNA Revenue 2020-2031 (US$ Million)
Figure 25. North America Viral Vector and Plasmid DNA Revenue Market Share by Type (2020-2025)
Figure 26. North America Viral Vector and Plasmid DNA Revenue Market Share by Application (2020-2025)
Figure 27. Asia-Pacific Viral Vector and Plasmid DNA Revenue 2020-2031 (US$ Million)
Figure 28. Asia-Pacific Viral Vector and Plasmid DNA Revenue Market Share by Region (2020-2031)
Figure 29. Asia-Pacific Viral Vector and Plasmid DNA Revenue Market Share by Type (2020-2025)
Figure 30. Asia-Pacific Viral Vector and Plasmid DNA Revenue Market Share by Application (2020-2025)
Figure 31. Europe Viral Vector and Plasmid DNA Revenue Growth Rate 2020-2031 (US$ Million)
Figure 32. Europe Viral Vector and Plasmid DNA Revenue Market Share by Country (2020-2031)
Figure 33. Europe Viral Vector and Plasmid DNA Revenue Market Share by Type (2020-2025)
Figure 34. Europe Viral Vector and Plasmid DNA Revenue Market Share by Application (2020-2025)
Figure 35. Latin America Viral Vector and Plasmid DNA Revenue Growth Rate 2020-2031 (US$ Million)
Figure 36. Latin America Viral Vector and Plasmid DNA Revenue Market Share by Country (2020-2031)
Figure 37. Latin America Viral Vector and Plasmid DNA Revenue Market Share by Type (2020-2025)
Figure 38. Latin America Viral Vector and Plasmid DNA Revenue Market Share by Application (2020-2025)
Figure 39. Middle East and Africa Viral Vector and Plasmid DNA Revenue Growth Rate 2020-2031 (US$ Million)
Figure 40. Middle East and Africa Viral Vector and Plasmid DNA Revenue Market Share by Country (2020-2031)
Figure 41. Middle East and Africa Viral Vector and Plasmid DNA Revenue Market Share by Type (2020-2025)
Figure 42. Middle East and Africa Viral Vector and Plasmid DNA Revenue Market Share by Application (2020-2025)
Figure 43. Viral Vector and Plasmid DNA Supply Chain (Upstream and Downstream Market)
Figure 44. Global Production Market Share of Viral Vector and Plasmid DNA Raw Materials by Region in 2024
Figure 45. Viral Vector and Plasmid DNA Distribution Channels
Figure 46. Global Viral Vector and Plasmid DNA Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 47. Global Viral Vector and Plasmid DNA Percentage 2020-2031: Online Sales VS Offline Sales
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed
Table 1. Global Viral Vector and Plasmid DNA Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Viral Vector and Plasmid DNA Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Viral Vector and Plasmid DNA Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Viral Vector and Plasmid DNA Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Viral Vector and Plasmid DNA Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Viral Vector and Plasmid DNA Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Viral Vector and Plasmid DNA Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Viral Vector and Plasmid DNA Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Viral Vector and Plasmid DNA Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Viral Vector and Plasmid DNA Revenue by Company (2020-2025) & (US$ Million)
Table 11. Viral Vector and Plasmid DNA Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Viral Vector and Plasmid DNA Players by Revenue (US$ Million) in 2024
Table 13. Global Viral Vector and Plasmid DNA Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Viral Vector and Plasmid DNA by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector and Plasmid DNA as of 2024)
Table 15. Global Viral Vector and Plasmid DNA Companies Headquarters
Table 16. Date of International Companies Enter into Viral Vector and Plasmid DNA Market
Table 17. Global Viral Vector and Plasmid DNA Companies Product & Service
Table 18. Global Viral Vector and Plasmid DNA Mergers & Acquisitions, Expansion Plans
Table 19. Brammer Bio Corporation Information
Table 20. Brammer Bio Description and Business Overview
Table 21. Brammer Bio Viral Vector and Plasmid DNA Product
Table 22. Brammer Bio Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Brammer Bio Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 24. Brammer Bio Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 25. Brammer Bio Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 26. Brammer Bio Recent Developments
Table 27. Oxford BioMedica Corporation Information
Table 28. Oxford BioMedica Description and Business Overview
Table 29. Oxford BioMedica Viral Vector and Plasmid DNA Product
Table 30. Oxford BioMedica Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Oxford BioMedica Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 32. Oxford BioMedica Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 33. Oxford BioMedica Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 34. Oxford BioMedica Recent Developments
Table 35. Cobra Biologics Corporation Information
Table 36. Cobra Biologics Description and Business Overview
Table 37. Cobra Biologics Viral Vector and Plasmid DNA Product
Table 38. Cobra Biologics Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Cobra Biologics Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 40. Cobra Biologics Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 41. Cobra Biologics Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 42. Cobra Biologics Recent Developments
Table 43. FinVector Corporation Information
Table 44. FinVector Description and Business Overview
Table 45. FinVector Viral Vector and Plasmid DNA Product
Table 46. FinVector Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. FinVector Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 48. FinVector Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 49. FinVector Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 50. FinVector Recent Developments
Table 51. Lonza Corporation Information
Table 52. Lonza Description and Business Overview
Table 53. Lonza Viral Vector and Plasmid DNA Product
Table 54. Lonza Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Lonza Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 56. Lonza Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 57. Lonza Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 58. Lonza Recent Developments
Table 59. BioReliance Corporation Information
Table 60. BioReliance Description and Business Overview
Table 61. BioReliance Viral Vector and Plasmid DNA Product
Table 62. BioReliance Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. BioReliance Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 64. BioReliance Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 65. BioReliance Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 66. BioReliance Recent Developments
Table 67. MolMed Corporation Information
Table 68. MolMed Description and Business Overview
Table 69. MolMed Viral Vector and Plasmid DNA Product
Table 70. MolMed Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. MolMed Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 72. MolMed Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 73. MolMed Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 74. MolMed Recent Developments
Table 75. FUJIFILM Diosynth Biotechnologies Corporation Information
Table 76. FUJIFILM Diosynth Biotechnologies Description and Business Overview
Table 77. FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Product
Table 78. FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. FUJIFILM Diosynth Biotechnologies Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 80. FUJIFILM Diosynth Biotechnologies Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 81. FUJIFILM Diosynth Biotechnologies Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 82. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 83. UniQure Corporation Information
Table 84. UniQure Description and Business Overview
Table 85. UniQure Viral Vector and Plasmid DNA Product
Table 86. UniQure Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. UniQure Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 88. UniQure Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 89. UniQure Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 90. UniQure Recent Developments
Table 91. Aldevron Corporation Information
Table 92. Aldevron Description and Business Overview
Table 93. Aldevron Viral Vector and Plasmid DNA Product
Table 94. Aldevron Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. Aldevron Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 96. Aldevron Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 97. Aldevron Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 98. Aldevron Recent Developments
Table 99. Richter-Helm Corporation Information
Table 100. Richter-Helm Description and Business Overview
Table 101. Richter-Helm Viral Vector and Plasmid DNA Product
Table 102. Richter-Helm Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Richter-Helm Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 104. Richter-Helm Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 105. Richter-Helm Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 106. Richter-Helm Recent Developments
Table 107. Eurogentec Corporation Information
Table 108. Eurogentec Description and Business Overview
Table 109. Eurogentec Viral Vector and Plasmid DNA Product
Table 110. Eurogentec Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 111. Eurogentec Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 112. Eurogentec Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 113. Eurogentec Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 114. Eurogentec Recent Developments
Table 115. OBiO Technology Corporation Information
Table 116. OBiO Technology Description and Business Overview
Table 117. OBiO Technology Viral Vector and Plasmid DNA Product
Table 118. OBiO Technology Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 119. OBiO Technology Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 120. OBiO Technology Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 121. OBiO Technology Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 122. OBiO Technology Recent Developments
Table 123. Yposkesi Corporation Information
Table 124. Yposkesi Description and Business Overview
Table 125. Yposkesi Viral Vector and Plasmid DNA Product
Table 126. Yposkesi Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 127. Yposkesi Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 128. Yposkesi Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 129. Yposkesi Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 130. Yposkesi Recent Developments
Table 131. Cell and Gene Therapy Catapult Corporation Information
Table 132. Cell and Gene Therapy Catapult Description and Business Overview
Table 133. Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Product
Table 134. Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 135. Cell and Gene Therapy Catapult Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 136. Cell and Gene Therapy Catapult Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 137. Cell and Gene Therapy Catapult Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 138. Cell and Gene Therapy Catapult Recent Developments
Table 139. MassBiologics Corporation Information
Table 140. MassBiologics Description and Business Overview
Table 141. MassBiologics Viral Vector and Plasmid DNA Product
Table 142. MassBiologics Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. MassBiologics Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 144. MassBiologics Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 145. MassBiologics Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 146. MassBiologics Recent Developments
Table 147. Biovian Corporation Information
Table 148. Biovian Description and Business Overview
Table 149. Biovian Viral Vector and Plasmid DNA Product
Table 150. Biovian Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 151. Biovian Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 152. Biovian Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 153. Biovian Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 154. Biovian Recent Developments
Table 155. VGXI Corporation Information
Table 156. VGXI Description and Business Overview
Table 157. VGXI Viral Vector and Plasmid DNA Product
Table 158. VGXI Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 159. VGXI Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 160. VGXI Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 161. VGXI Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 162. VGXI Recent Developments
Table 163. Gene Synthesis Corporation Information
Table 164. Gene Synthesis Description and Business Overview
Table 165. Gene Synthesis Viral Vector and Plasmid DNA Product
Table 166. Gene Synthesis Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 167. Gene Synthesis Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 168. Gene Synthesis Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 169. Gene Synthesis Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 170. Gene Synthesis Recent Developments
Table 171. PlasmidFactory Corporation Information
Table 172. PlasmidFactory Description and Business Overview
Table 173. PlasmidFactory Viral Vector and Plasmid DNA Product
Table 174. PlasmidFactory Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 175. PlasmidFactory Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 176. PlasmidFactory Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 177. PlasmidFactory Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 178. PlasmidFactory Recent Developments
Table 179. Jikai Gene Corporation Information
Table 180. Jikai Gene Description and Business Overview
Table 181. Jikai Gene Viral Vector and Plasmid DNA Product
Table 182. Jikai Gene Viral Vector and Plasmid DNA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 183. Jikai Gene Revenue Proportion of Viral Vector and Plasmid DNA by Product in 2024
Table 184. Jikai Gene Revenue Proportion of Viral Vector and Plasmid DNA by Application in 2024
Table 185. Jikai Gene Revenue Proportion of Viral Vector and Plasmid DNA by Geographic Area in 2024
Table 186. Jikai Gene Recent Developments
Table 187. North America Viral Vector and Plasmid DNA Revenue by Country (2020-2025) & (US$ Million)
Table 188. North America Viral Vector and Plasmid DNA Revenue by Country (2026-2031) & (US$ Million)
Table 189. North America Viral Vector and Plasmid DNA Revenue by Type (2020-2025) & (US$ Million)
Table 190. North America Viral Vector and Plasmid DNA Revenue by Application (2020-2025) & (US$ Million)
Table 191. Asia-Pacific Viral Vector and Plasmid DNA Revenue by Region (2020-2025) & (US$ Million)
Table 192. Asia-Pacific Viral Vector and Plasmid DNA Revenue by Region (2026-2031) & (US$ Million)
Table 193. Asia-Pacific Viral Vector and Plasmid DNA Revenue by Type (2020-2025) & (US$ Million)
Table 194. Asia-Pacific Viral Vector and Plasmid DNA Revenue by Application (2020-2025) & (US$ Million)
Table 195. Europe Viral Vector and Plasmid DNA Revenue by Country (2020-2025) & (US$ Million)
Table 196. Europe Viral Vector and Plasmid DNA Revenue by Country (2026-2031) & (US$ Million)
Table 197. Europe Viral Vector and Plasmid DNA Revenue by Type (2020-2025) & (US$ Million)
Table 198. Europe Viral Vector and Plasmid DNA Revenue by Application (2020-2025) & (US$ Million)
Table 199. Latin America Viral Vector and Plasmid DNA Revenue by Country (2020-2025) & (US$ Million)
Table 200. Latin America Viral Vector and Plasmid DNA Revenue by Country (2026-2031) & (US$ Million)
Table 201. Latin America Viral Vector and Plasmid DNA Revenue by Type (2020-2025) & (US$ Million)
Table 202. Latin America Viral Vector and Plasmid DNA Revenue by Application (2020-2025) & (US$ Million)
Table 203. Middle East and Africa Viral Vector and Plasmid DNA Revenue by Country (2020-2025) & (US$ Million)
Table 204. Middle East and Africa Viral Vector and Plasmid DNA Revenue by Country (2026-2031) & (US$ Million)
Table 205. Middle East and Africa Viral Vector and Plasmid DNA Revenue by Type (2020-2025) & (US$ Million)
Table 206. Middle East and Africa Viral Vector and Plasmid DNA Revenue by Application (2020-2025) & (US$ Million)
Table 207. Viral Vector and Plasmid DNA Key Raw Materials, Industry Status and Trend
Table 208. Viral Vector and Plasmid DNA Key Raw Materials and Upstream Suppliers
Table 209. Viral Vector and Plasmid DNA Clients Status and Trend
Table 210. Viral Vector and Plasmid DNA Typical Clients
Table 211. Viral Vector and Plasmid DNA Distributors
Table 212. Viral Vector and Plasmid DNA Market Trends
Table 213. Viral Vector and Plasmid DNA Market Drivers
Table 214. Viral Vector and Plasmid DNA Market Challenges
Table 215. Viral Vector and Plasmid DNA Market Restraints
Table 216. Research Programs/Design for This Report
Table 217. Key Data Information from Secondary Sources
Table 218. Key Data Information from Primary Sources
List of Figures
Figure 1. Viral Vector and Plasmid DNA Product Picture
Figure 2. Global Viral Vector and Plasmid DNA Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Viral Vector and Plasmid DNA Revenue Market Share by Type in 2024 & 2031
Figure 4. Plasmid DNA Product Picture
Figure 5. Viral Vector Product Picture
Figure 6. Global Viral Vector and Plasmid DNA Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 7. Global Viral Vector and Plasmid DNA Revenue Market Share by Application in 2024 & 2031
Figure 8. Cancer
Figure 9. Virus Infection
Figure 10. Hereditary Disease
Figure 11. Viral Vector and Plasmid DNA Report Years Considered
Figure 12. Global Viral Vector and Plasmid DNA Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Viral Vector and Plasmid DNA Market Size (2020-2031) & (US$ Million)
Figure 14. Global Viral Vector and Plasmid DNA Market Size Market Share by Region: 2024 Versus 2031
Figure 15. Global Viral Vector and Plasmid DNA Revenue Market Share by Region (2020-2031)
Figure 16. Global Viral Vector and Plasmid DNA Revenue Market Share Forecast by Type (2020-2031)
Figure 17. Global Viral Vector and Plasmid DNA Revenue Market Share Forecast by Application (2020-2031)
Figure 18. Plasmid DNA of Viral Vector and Plasmid DNA Revenue Market Share by Application, 2024 VS 2031
Figure 19. Viral Vector of Viral Vector and Plasmid DNA Revenue Market Share by Application, 2024 VS 2031
Figure 20. Viral Vector and Plasmid DNA Revenue Share by Company (2024)
Figure 21. Viral Vector and Plasmid DNA Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. Plasmid DNA Revenue Proportion by Company in 2024
Figure 23. Viral Vector Revenue Proportion by Company in 2024
Figure 24. North America Viral Vector and Plasmid DNA Revenue 2020-2031 (US$ Million)
Figure 25. North America Viral Vector and Plasmid DNA Revenue Market Share by Type (2020-2025)
Figure 26. North America Viral Vector and Plasmid DNA Revenue Market Share by Application (2020-2025)
Figure 27. Asia-Pacific Viral Vector and Plasmid DNA Revenue 2020-2031 (US$ Million)
Figure 28. Asia-Pacific Viral Vector and Plasmid DNA Revenue Market Share by Region (2020-2031)
Figure 29. Asia-Pacific Viral Vector and Plasmid DNA Revenue Market Share by Type (2020-2025)
Figure 30. Asia-Pacific Viral Vector and Plasmid DNA Revenue Market Share by Application (2020-2025)
Figure 31. Europe Viral Vector and Plasmid DNA Revenue Growth Rate 2020-2031 (US$ Million)
Figure 32. Europe Viral Vector and Plasmid DNA Revenue Market Share by Country (2020-2031)
Figure 33. Europe Viral Vector and Plasmid DNA Revenue Market Share by Type (2020-2025)
Figure 34. Europe Viral Vector and Plasmid DNA Revenue Market Share by Application (2020-2025)
Figure 35. Latin America Viral Vector and Plasmid DNA Revenue Growth Rate 2020-2031 (US$ Million)
Figure 36. Latin America Viral Vector and Plasmid DNA Revenue Market Share by Country (2020-2031)
Figure 37. Latin America Viral Vector and Plasmid DNA Revenue Market Share by Type (2020-2025)
Figure 38. Latin America Viral Vector and Plasmid DNA Revenue Market Share by Application (2020-2025)
Figure 39. Middle East and Africa Viral Vector and Plasmid DNA Revenue Growth Rate 2020-2031 (US$ Million)
Figure 40. Middle East and Africa Viral Vector and Plasmid DNA Revenue Market Share by Country (2020-2031)
Figure 41. Middle East and Africa Viral Vector and Plasmid DNA Revenue Market Share by Type (2020-2025)
Figure 42. Middle East and Africa Viral Vector and Plasmid DNA Revenue Market Share by Application (2020-2025)
Figure 43. Viral Vector and Plasmid DNA Supply Chain (Upstream and Downstream Market)
Figure 44. Global Production Market Share of Viral Vector and Plasmid DNA Raw Materials by Region in 2024
Figure 45. Viral Vector and Plasmid DNA Distribution Channels
Figure 46. Global Viral Vector and Plasmid DNA Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 47. Global Viral Vector and Plasmid DNA Percentage 2020-2031: Online Sales VS Offline Sales
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Allergen Detection Market Research Report 2025
Jun 28, 25
Global Electronic Health Tracking System Market Research Report 2025
Jun 28, 25
Global Speciality Optical Fibers Market Research Report 2025
Jun 28, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232